Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
William Meury is Chief Executive Officer at Incyte. OQRO lists 5 transactions filed with the SEC under this name, the latest on Jul 20, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
5
Companies involved
1
William Meury has no open-market purchase on record since 2023. Sales in 1 of the 4 years since 2023.
William Meury reported 0 open-market purchases and 3 sales since 2023; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $1.7M3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
IncyteINCY
5 disclosures · Apr 2026 – Jul 2026
Jul 16, 202627Kdisclosed Jul 20
DetailsOfficial recordJul 16, 202680Kdisclosed Jul 20
DetailsOfficial recordJul 16, 202677Kdisclosed Jul 20
DetailsOfficial recordJul 2, 20264,779disclosed Jul 7
DetailsOfficial recordApr 15, 2026125Kdisclosed Apr 17
DetailsOfficial recordAs of the latest filing on , William Meury reported holding 183,129 shares of Incyte (INCY), worth about $21.2M at the last close of $116 (Nov 19, 2026).
Incyte's proxy statement reports total compensation of $32.1M for William Meury for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 28, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Incyte INCY | 183,129 | 183K direct | $116 | $21.2M | Jul 16, 2026 |
Is this William Meury’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jul 16, 2026, William Meury reported holding 183,129 shares of Incyte (INCY). At the last close of $116 on Nov 19, 2026, that is about $21.2M. This is the stake disclosed in filings, not a net worth.
No public filing gives William Meury's net worth. What SEC Form 4 shows is the stock stake: 183,129 shares of Incyte (INCY), about $21.2M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Incyte's proxy statement reports total compensation of $32.1M for William Meury for fiscal year 2025. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
William Meury has no open-market purchase on record since 2023. Sales in 1 of the 4 years since 2023.
In SEC filings since 2023: no open-market purchase is on record; the latest open-market sale is from 2023.
Syndax Pharmaceuticals (SNDX), from 2023 to 2023: 0 purchases and 3 sales.
William Meury reported 0 open-market purchases and 3 sales here, 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.